Crossmark

Dual pathway inhibition with faricimab for previously treated neovascular age-related macular degeneration and diabetic macular oedema: guidance from a UK panel of retina specialists

Crossref DOI link: https://doi.org/10.1038/s41433-024-03223-w

Published Online: 2024-08-30

Published Print: 2024-11

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Downey, Louise

Sivaprasad, Sobha https://orcid.org/0000-0001-8952-0659
Chhabra, Ramandeep

Bailey, Clare https://orcid.org/0000-0003-2141-4512
Chakrabarti, Soma

Elsherbiny, Samer

Patel, Jignesh

Silvestri, Giuliana https://orcid.org/0000-0001-5662-5374
Watson, Sarah-Lucie

Williams, Gwyn

Parker, Antony

Khokhar, Saima

Lotery, Andrew https://orcid.org/0000-0001-5541-4305
License Information

Text and Data Mining valid from 2024-08-30

Version of Record valid from 2024-08-30
More Information

Article History

Received: 12 March 2024

Revised: 16 May 2024

Accepted: 3 July 2024

First Online: 30 August 2024

Competing interests

: LD: Advisory board attendances for and speaker honoraria from Alimera Sciences, AbbVie, Bayer, Biogen, Novartis and Roche; travel grants from AbbVie, Bayer and Novartis. SS: Financial support from AbbVie, Amgen, Apellis, Bayer, Biogen, Boehringer Ingelheim, Novartis, Eyebiotech, EyePoint Pharmaceuticals, Janssen Pharmaceuticals, Nova Nordisk, Optos, Ocular Therapeutix, Kriya Therapeutics, OcuTerra, Roche, Stealth Biotherapeutics and Sanofi. Is the current Editor in Chief of Eye. RC: Advisory board attendances for and speaker honoraria and travel grants from Roche, Bayer, Novartis and Alimera Sciences. CB: Advisory board attendances for and honoraria and travel support from Alimera Sciences, Apellis, Bayer, Boehringer Ingelheim, Janssen Pharmaceuticals, Novartis and Roche. SC: Honoraria from and consultancy for Roche, AbbVie and Alimera Sciences and travel support from Bayer and Alimera Sciences. SE: Advisory board attendances for and travel support from AbbVie, Alimera Sciences, Bayer, Novartis, Roche and Topcon. JP: Consultancy for and travel support from Bayer and Roche. GS: Advisory board attendances for and honoraria and travel support from Bayer and Roche. S-LW: Advisory board attendances for and honoraria and travel support from Roche, Bayer, and Novartis. GW: Honoraria from Roche. AP: Employee of Roche Products Limited. SK: Employee of Roche Products Limited. AL: Travel support from Roche; equity in EyeBio.

Document is current

Any future updates will be listed below